| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 165 | 2024 | 2157 | 10.490 |
Why?
|
| Veterans | 89 | 2024 | 1779 | 3.900 |
Why?
|
| Pneumococcal Vaccines | 15 | 2016 | 184 | 2.750 |
Why?
|
| Anti-HIV Agents | 28 | 2020 | 353 | 1.840 |
Why?
|
| Antiretroviral Therapy, Highly Active | 27 | 2021 | 309 | 1.660 |
Why?
|
| Antibodies, Bacterial | 12 | 2016 | 420 | 1.380 |
Why?
|
| CD4 Lymphocyte Count | 28 | 2022 | 296 | 1.320 |
Why?
|
| Pneumonia, Pneumococcal | 4 | 2014 | 93 | 1.290 |
Why?
|
| Anti-Retroviral Agents | 9 | 2017 | 145 | 1.160 |
Why?
|
| Delivery of Health Care | 10 | 2022 | 876 | 0.960 |
Why?
|
| Respiratory Protective Devices | 2 | 2021 | 15 | 0.950 |
Why?
|
| Respiratory Tract Infections | 5 | 2022 | 408 | 0.910 |
Why?
|
| Hepatitis C | 12 | 2020 | 551 | 0.890 |
Why?
|
| Middle Aged | 162 | 2024 | 90427 | 0.870 |
Why?
|
| Aging | 15 | 2022 | 1578 | 0.840 |
Why?
|
| Cohort Studies | 62 | 2024 | 9494 | 0.840 |
Why?
|
| Acquired Immunodeficiency Syndrome | 4 | 2021 | 370 | 0.830 |
Why?
|
| Viral Load | 21 | 2020 | 482 | 0.800 |
Why?
|
| Osteomyelitis | 3 | 2019 | 260 | 0.770 |
Why?
|
| Fractures, Bone | 6 | 2023 | 312 | 0.770 |
Why?
|
| HIV-1 | 21 | 2018 | 641 | 0.760 |
Why?
|
| Male | 178 | 2024 | 128995 | 0.760 |
Why?
|
| Acute Coronary Syndrome | 2 | 2024 | 256 | 0.750 |
Why?
|
| RNA, Viral | 13 | 2020 | 729 | 0.740 |
Why?
|
| Lymphadenopathy | 1 | 2021 | 94 | 0.730 |
Why?
|
| Humans | 227 | 2024 | 271941 | 0.730 |
Why?
|
| Myocardial Infarction | 6 | 2020 | 1304 | 0.720 |
Why?
|
| Adult | 129 | 2024 | 81889 | 0.710 |
Why?
|
| Veterans Health | 8 | 2020 | 179 | 0.710 |
Why?
|
| Health Personnel | 10 | 2021 | 651 | 0.690 |
Why?
|
| Streptococcus pneumoniae | 11 | 2016 | 404 | 0.670 |
Why?
|
| Liver Cirrhosis | 8 | 2020 | 1033 | 0.650 |
Why?
|
| Alcoholism | 5 | 2023 | 330 | 0.650 |
Why?
|
| Influenza, Human | 6 | 2022 | 763 | 0.640 |
Why?
|
| Bone Diseases | 1 | 2019 | 142 | 0.630 |
Why?
|
| Medication Adherence | 9 | 2018 | 519 | 0.630 |
Why?
|
| AIDS-Related Opportunistic Infections | 12 | 2015 | 190 | 0.610 |
Why?
|
| Daptomycin | 1 | 2018 | 39 | 0.610 |
Why?
|
| United States | 64 | 2024 | 16053 | 0.600 |
Why?
|
| Bacterial Translocation | 1 | 2017 | 28 | 0.600 |
Why?
|
| Diabetic Foot | 3 | 2019 | 157 | 0.600 |
Why?
|
| Bacteria | 3 | 2023 | 652 | 0.590 |
Why?
|
| Female | 142 | 2024 | 149187 | 0.580 |
Why?
|
| Risk Factors | 45 | 2024 | 18047 | 0.580 |
Why?
|
| Lipopolysaccharide Receptors | 6 | 2017 | 90 | 0.580 |
Why?
|
| Vaccines, Conjugate | 4 | 2014 | 83 | 0.570 |
Why?
|
| HIV Seropositivity | 9 | 2013 | 154 | 0.550 |
Why?
|
| Gastroenteritis | 4 | 2021 | 353 | 0.540 |
Why?
|
| Alcohol-Related Disorders | 4 | 2020 | 43 | 0.540 |
Why?
|
| Alcohol Drinking | 10 | 2023 | 600 | 0.530 |
Why?
|
| Patient Compliance | 5 | 2013 | 681 | 0.520 |
Why?
|
| Hospitals, Veterans | 8 | 2021 | 380 | 0.510 |
Why?
|
| Bone and Bones | 1 | 2019 | 613 | 0.510 |
Why?
|
| Vaccination | 10 | 2024 | 1156 | 0.500 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2018 | 289 | 0.490 |
Why?
|
| Telemedicine | 2 | 2019 | 549 | 0.490 |
Why?
|
| Proton Pump Inhibitors | 1 | 2017 | 272 | 0.490 |
Why?
|
| Substance-Related Disorders | 6 | 2024 | 550 | 0.490 |
Why?
|
| Cardiovascular Diseases | 5 | 2020 | 2307 | 0.470 |
Why?
|
| Longitudinal Studies | 22 | 2024 | 2053 | 0.470 |
Why?
|
| HIV | 8 | 2020 | 236 | 0.470 |
Why?
|
| Incidence | 21 | 2022 | 5861 | 0.470 |
Why?
|
| Pneumococcal Infections | 8 | 2016 | 300 | 0.470 |
Why?
|
| Developed Countries | 1 | 2014 | 46 | 0.470 |
Why?
|
| CD4-Positive T-Lymphocytes | 5 | 2020 | 1054 | 0.450 |
Why?
|
| Primary Health Care | 8 | 2020 | 843 | 0.450 |
Why?
|
| United States Department of Veterans Affairs | 16 | 2024 | 678 | 0.440 |
Why?
|
| Electronic Health Records | 5 | 2018 | 969 | 0.440 |
Why?
|
| Pneumonia | 4 | 2023 | 798 | 0.440 |
Why?
|
| Osteoporotic Fractures | 4 | 2023 | 39 | 0.430 |
Why?
|
| Immunoglobulin G | 9 | 2016 | 1140 | 0.430 |
Why?
|
| Lymphocyte Activation | 2 | 2017 | 1728 | 0.430 |
Why?
|
| Pneumonia, Viral | 2 | 2018 | 709 | 0.430 |
Why?
|
| Polypharmacy | 3 | 2022 | 63 | 0.420 |
Why?
|
| Community-Acquired Infections | 4 | 2020 | 286 | 0.420 |
Why?
|
| Hepatitis C, Chronic | 6 | 2018 | 469 | 0.420 |
Why?
|
| Caliciviridae Infections | 3 | 2021 | 317 | 0.400 |
Why?
|
| Aged | 62 | 2024 | 73494 | 0.380 |
Why?
|
| Prospective Studies | 28 | 2022 | 13402 | 0.380 |
Why?
|
| Herpes Zoster | 2 | 2024 | 53 | 0.380 |
Why?
|
| Bacterial Vaccines | 6 | 1998 | 118 | 0.370 |
Why?
|
| Algorithms | 8 | 2016 | 3924 | 0.370 |
Why?
|
| Hospitalization | 8 | 2022 | 2202 | 0.370 |
Why?
|
| International Classification of Diseases | 4 | 2020 | 95 | 0.370 |
Why?
|
| Coinfection | 6 | 2019 | 202 | 0.360 |
Why?
|
| Bacteremia | 4 | 2018 | 722 | 0.360 |
Why?
|
| Biomarkers | 15 | 2021 | 5114 | 0.360 |
Why?
|
| Serum Globulins | 1 | 2010 | 7 | 0.360 |
Why?
|
| Masks | 2 | 2021 | 56 | 0.350 |
Why?
|
| Motivational Interviewing | 3 | 2020 | 47 | 0.350 |
Why?
|
| Smoking | 9 | 2016 | 2538 | 0.340 |
Why?
|
| Depression | 7 | 2016 | 1736 | 0.330 |
Why?
|
| Bartonella | 4 | 1997 | 13 | 0.330 |
Why?
|
| Frailty | 2 | 2023 | 133 | 0.320 |
Why?
|
| Polysaccharides, Bacterial | 3 | 2006 | 73 | 0.320 |
Why?
|
| Meningococcal Vaccines | 1 | 2008 | 31 | 0.320 |
Why?
|
| Blood Proteins | 1 | 2010 | 301 | 0.320 |
Why?
|
| Pneumonia, Bacterial | 5 | 2016 | 135 | 0.310 |
Why?
|
| Case-Control Studies | 14 | 2022 | 6236 | 0.310 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 6 | 2021 | 1060 | 0.310 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 4 | 2017 | 66 | 0.300 |
Why?
|
| Comorbidity | 17 | 2019 | 2439 | 0.290 |
Why?
|
| Cross-Sectional Studies | 17 | 2022 | 4509 | 0.290 |
Why?
|
| Counseling | 5 | 2019 | 385 | 0.290 |
Why?
|
| Syphilis | 2 | 2017 | 98 | 0.280 |
Why?
|
| Influenza Vaccines | 2 | 2022 | 492 | 0.280 |
Why?
|
| Monocytes | 4 | 2016 | 789 | 0.270 |
Why?
|
| HIV Long-Term Survivors | 2 | 2020 | 6 | 0.270 |
Why?
|
| Bone Density | 5 | 2023 | 470 | 0.260 |
Why?
|
| Population Surveillance | 3 | 2021 | 650 | 0.260 |
Why?
|
| Heart Failure | 5 | 2020 | 2500 | 0.260 |
Why?
|
| Intensive Care Units | 4 | 2022 | 743 | 0.260 |
Why?
|
| Stroke Volume | 2 | 2020 | 578 | 0.260 |
Why?
|
| Proportional Hazards Models | 13 | 2024 | 5118 | 0.260 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 2017 | 204 | 0.250 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2021 | 852 | 0.250 |
Why?
|
| Depressive Disorder | 3 | 2016 | 566 | 0.240 |
Why?
|
| Drug Prescriptions | 3 | 2019 | 321 | 0.240 |
Why?
|
| Glycerophospholipids | 2 | 2021 | 7 | 0.240 |
Why?
|
| Neoplasms | 6 | 2022 | 15928 | 0.230 |
Why?
|
| Treatment Failure | 2 | 2019 | 1432 | 0.230 |
Why?
|
| Norovirus | 2 | 2020 | 304 | 0.230 |
Why?
|
| Lung Diseases | 3 | 2020 | 755 | 0.220 |
Why?
|
| Branched DNA Signal Amplification Assay | 1 | 2003 | 2 | 0.220 |
Why?
|
| Anti-Bacterial Agents | 6 | 2022 | 3176 | 0.220 |
Why?
|
| Interleukin-6 | 4 | 2017 | 1066 | 0.220 |
Why?
|
| Bacteriology | 1 | 2023 | 4 | 0.220 |
Why?
|
| Accidental Falls | 2 | 2022 | 143 | 0.220 |
Why?
|
| Data Collection | 5 | 2013 | 624 | 0.220 |
Why?
|
| Sleep Wake Disorders | 2 | 2017 | 372 | 0.220 |
Why?
|
| Blood Coagulation Disorders | 2 | 2016 | 116 | 0.220 |
Why?
|
| Antidepressive Agents | 4 | 2017 | 337 | 0.210 |
Why?
|
| Diabetes Complications | 2 | 2012 | 316 | 0.210 |
Why?
|
| Nucleic Acids | 1 | 2023 | 44 | 0.210 |
Why?
|
| Salmonella Infections | 2 | 2013 | 43 | 0.210 |
Why?
|
| Staphylococcal Infections | 2 | 2019 | 682 | 0.210 |
Why?
|
| HIV Protease Inhibitors | 2 | 2016 | 74 | 0.210 |
Why?
|
| Absorptiometry, Photon | 2 | 2022 | 237 | 0.210 |
Why?
|
| Inflammation | 4 | 2017 | 2534 | 0.210 |
Why?
|
| Weight Gain | 2 | 2016 | 474 | 0.210 |
Why?
|
| Azithromycin | 1 | 2022 | 79 | 0.210 |
Why?
|
| Carcinoma, Hepatocellular | 5 | 2020 | 2174 | 0.200 |
Why?
|
| Texas | 9 | 2020 | 6435 | 0.200 |
Why?
|
| Coronavirus OC43, Human | 1 | 2021 | 13 | 0.200 |
Why?
|
| Depressive Disorder, Major | 2 | 2019 | 429 | 0.200 |
Why?
|
| Hip Fractures | 1 | 2023 | 88 | 0.200 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2022 | 70 | 0.200 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2015 | 604 | 0.200 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2020 | 169 | 0.190 |
Why?
|
| Aged, 80 and over | 19 | 2023 | 31060 | 0.190 |
Why?
|
| Outpatients | 2 | 2021 | 469 | 0.190 |
Why?
|
| Age Factors | 13 | 2020 | 5521 | 0.190 |
Why?
|
| Antibodies, Viral | 3 | 2022 | 1296 | 0.180 |
Why?
|
| Attitude | 1 | 2021 | 163 | 0.180 |
Why?
|
| Communicable Diseases | 1 | 2023 | 210 | 0.180 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2020 | 1659 | 0.170 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2022 | 216 | 0.170 |
Why?
|
| Antiviral Agents | 4 | 2018 | 1255 | 0.170 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2016 | 1435 | 0.170 |
Why?
|
| Cannabis | 1 | 2020 | 70 | 0.170 |
Why?
|
| Analgesics, Opioid | 3 | 2019 | 1458 | 0.170 |
Why?
|
| Patient Admission | 2 | 2019 | 236 | 0.170 |
Why?
|
| Risk Assessment | 12 | 2023 | 6883 | 0.170 |
Why?
|
| Self Report | 4 | 2021 | 796 | 0.170 |
Why?
|
| Patient Satisfaction | 3 | 2016 | 916 | 0.170 |
Why?
|
| Viruses | 1 | 2021 | 156 | 0.170 |
Why?
|
| Infection Control | 2 | 2019 | 276 | 0.170 |
Why?
|
| Physician-Patient Relations | 2 | 2016 | 736 | 0.170 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2019 | 59 | 0.160 |
Why?
|
| Indinavir | 1 | 1998 | 8 | 0.160 |
Why?
|
| Retrospective Studies | 18 | 2022 | 39800 | 0.160 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2019 | 82 | 0.160 |
Why?
|
| Gynecomastia | 1 | 1998 | 11 | 0.160 |
Why?
|
| Survival Analysis | 10 | 2019 | 9325 | 0.160 |
Why?
|
| Defibrillators, Implantable | 1 | 2022 | 227 | 0.160 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2018 | 12 | 0.160 |
Why?
|
| Enterococcus | 1 | 2019 | 61 | 0.160 |
Why?
|
| Severity of Illness Index | 10 | 2020 | 4399 | 0.160 |
Why?
|
| Vaccination Coverage | 1 | 2018 | 36 | 0.160 |
Why?
|
| Prevalence | 10 | 2019 | 3426 | 0.160 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2019 | 41 | 0.160 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2024 | 369 | 0.160 |
Why?
|
| Young Adult | 16 | 2022 | 22127 | 0.160 |
Why?
|
| Secondary Prevention | 1 | 2020 | 322 | 0.160 |
Why?
|
| Pharmacy | 1 | 2018 | 14 | 0.160 |
Why?
|
| Patient Care Team | 2 | 2016 | 830 | 0.160 |
Why?
|
| Treatment Outcome | 20 | 2024 | 33874 | 0.160 |
Why?
|
| Mandatory Programs | 1 | 2018 | 6 | 0.160 |
Why?
|
| Rotavirus | 1 | 2021 | 498 | 0.150 |
Why?
|
| Methicillin | 1 | 2018 | 46 | 0.150 |
Why?
|
| Pharmacoepidemiology | 2 | 2018 | 8 | 0.150 |
Why?
|
| Confidence Intervals | 4 | 2014 | 758 | 0.150 |
Why?
|
| Quality of Health Care | 2 | 2013 | 632 | 0.150 |
Why?
|
| Surveys and Questionnaires | 12 | 2017 | 5929 | 0.150 |
Why?
|
| Bacteroides Infections | 1 | 1997 | 10 | 0.150 |
Why?
|
| Bacteroides fragilis | 1 | 1997 | 7 | 0.150 |
Why?
|
| Anti-Infective Agents | 1 | 2022 | 465 | 0.150 |
Why?
|
| Acute-Phase Proteins | 1 | 2017 | 85 | 0.150 |
Why?
|
| Immunoglobulin Allotypes | 2 | 1997 | 9 | 0.150 |
Why?
|
| Protease Inhibitors | 1 | 1998 | 207 | 0.150 |
Why?
|
| Liver Neoplasms | 4 | 2020 | 4811 | 0.150 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2016 | 1322 | 0.150 |
Why?
|
| Chondrocalcinosis | 1 | 1997 | 26 | 0.150 |
Why?
|
| Penicillin G Benzathine | 1 | 2017 | 19 | 0.140 |
Why?
|
| Time Factors | 9 | 2021 | 13130 | 0.140 |
Why?
|
| Crack Cocaine | 1 | 1996 | 5 | 0.140 |
Why?
|
| Pharyngitis | 1 | 1997 | 47 | 0.140 |
Why?
|
| Immunoglobulin M | 2 | 2016 | 362 | 0.140 |
Why?
|
| Cephalosporins | 1 | 2018 | 174 | 0.140 |
Why?
|
| Bilirubin | 1 | 2018 | 224 | 0.140 |
Why?
|
| Fatty Liver | 1 | 2019 | 257 | 0.140 |
Why?
|
| Parkinson Disease | 1 | 2024 | 694 | 0.140 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2018 | 1073 | 0.140 |
Why?
|
| HIV Seronegativity | 3 | 2009 | 35 | 0.140 |
Why?
|
| Respiratory Function Tests | 2 | 2018 | 355 | 0.140 |
Why?
|
| Fibronectins | 2 | 2009 | 210 | 0.140 |
Why?
|
| Arthritis, Infectious | 1 | 1997 | 75 | 0.140 |
Why?
|
| Locomotion | 1 | 2017 | 87 | 0.140 |
Why?
|
| Hepatitis B Core Antigens | 1 | 2016 | 28 | 0.140 |
Why?
|
| Bacterial Capsules | 2 | 1996 | 41 | 0.140 |
Why?
|
| Aspartate Aminotransferases | 4 | 2020 | 148 | 0.140 |
Why?
|
| Communicable Disease Control | 1 | 2018 | 175 | 0.140 |
Why?
|
| Hepatitis B Antibodies | 1 | 2016 | 56 | 0.130 |
Why?
|
| Ventricular Function, Left | 1 | 2020 | 580 | 0.130 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2016 | 89 | 0.130 |
Why?
|
| Cooperative Behavior | 3 | 2015 | 308 | 0.130 |
Why?
|
| Health Status | 3 | 2020 | 633 | 0.130 |
Why?
|
| Emphysema | 1 | 2017 | 88 | 0.130 |
Why?
|
| Fractures, Spontaneous | 1 | 2016 | 87 | 0.130 |
Why?
|
| Polymerase Chain Reaction | 4 | 1997 | 3512 | 0.130 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2015 | 75 | 0.130 |
Why?
|
| Intention | 2 | 2013 | 113 | 0.130 |
Why?
|
| Buprenorphine | 1 | 2016 | 100 | 0.120 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 312 | 0.120 |
Why?
|
| Ambulatory Care | 2 | 2019 | 606 | 0.120 |
Why?
|
| Hypolipidemic Agents | 2 | 2009 | 190 | 0.120 |
Why?
|
| Lipopolysaccharides | 1 | 2017 | 593 | 0.120 |
Why?
|
| Lung Neoplasms | 6 | 2019 | 12012 | 0.120 |
Why?
|
| DNA Fingerprinting | 1 | 1995 | 181 | 0.120 |
Why?
|
| Cost of Illness | 2 | 2020 | 505 | 0.120 |
Why?
|
| Phagocytosis | 4 | 2008 | 296 | 0.120 |
Why?
|
| Staphylococcus aureus | 1 | 2019 | 563 | 0.120 |
Why?
|
| Odds Ratio | 6 | 2019 | 2335 | 0.120 |
Why?
|
| Haemophilus influenzae type b | 1 | 2014 | 5 | 0.120 |
Why?
|
| Mass Screening | 2 | 2013 | 1547 | 0.120 |
Why?
|
| Haemophilus Vaccines | 1 | 2014 | 36 | 0.120 |
Why?
|
| CD4 Antigens | 1 | 2014 | 171 | 0.120 |
Why?
|
| Foot Diseases | 1 | 2014 | 49 | 0.120 |
Why?
|
| Membrane Glycoproteins | 2 | 2017 | 1105 | 0.120 |
Why?
|
| Quality Improvement | 1 | 2021 | 918 | 0.120 |
Why?
|
| Interleukin-2 | 2 | 2010 | 891 | 0.120 |
Why?
|
| Positive-Pressure Respiration | 1 | 2014 | 124 | 0.110 |
Why?
|
| Logistic Models | 6 | 2019 | 3469 | 0.110 |
Why?
|
| Gene Products, vpr | 1 | 2013 | 24 | 0.110 |
Why?
|
| Streptococcal Infections | 1 | 1997 | 312 | 0.110 |
Why?
|
| Haemophilus Infections | 1 | 2014 | 110 | 0.110 |
Why?
|
| Foot | 1 | 2014 | 108 | 0.110 |
Why?
|
| Prehypertension | 1 | 2013 | 16 | 0.110 |
Why?
|
| Respiratory Tract Diseases | 1 | 2014 | 111 | 0.110 |
Why?
|
| Salmonella enteritidis | 1 | 2013 | 8 | 0.110 |
Why?
|
| Sex Characteristics | 2 | 2013 | 434 | 0.110 |
Why?
|
| Obesity | 2 | 2017 | 2958 | 0.110 |
Why?
|
| Respiratory Insufficiency | 1 | 2017 | 347 | 0.110 |
Why?
|
| Polysomnography | 1 | 2014 | 178 | 0.110 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2016 | 273 | 0.110 |
Why?
|
| Early Detection of Cancer | 1 | 2021 | 1340 | 0.110 |
Why?
|
| Aneurysm, Infected | 1 | 2013 | 31 | 0.110 |
Why?
|
| Cough | 1 | 2014 | 126 | 0.110 |
Why?
|
| Pulmonary Emphysema | 1 | 2014 | 157 | 0.110 |
Why?
|
| Polysaccharides | 1 | 2014 | 195 | 0.110 |
Why?
|
| Ritonavir | 2 | 2016 | 66 | 0.110 |
Why?
|
| Viremia | 3 | 2020 | 182 | 0.110 |
Why?
|
| AIDS Serodiagnosis | 1 | 2013 | 57 | 0.110 |
Why?
|
| Observational Studies as Topic | 1 | 2013 | 148 | 0.100 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2015 | 277 | 0.100 |
Why?
|
| Liver Failure | 1 | 2013 | 141 | 0.100 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2013 | 211 | 0.100 |
Why?
|
| Integrin alpha5 | 2 | 2009 | 13 | 0.100 |
Why?
|
| Cytomegalovirus Infections | 1 | 1996 | 485 | 0.100 |
Why?
|
| Body Weight | 2 | 2015 | 1335 | 0.100 |
Why?
|
| Brain Ischemia | 1 | 2015 | 316 | 0.100 |
Why?
|
| Vasculitis | 1 | 2012 | 78 | 0.100 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 620 | 0.100 |
Why?
|
| Kidney Diseases | 3 | 2015 | 732 | 0.100 |
Why?
|
| Body Mass Index | 6 | 2017 | 2259 | 0.100 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 1992 | 88 | 0.100 |
Why?
|
| Alanine Transaminase | 3 | 2020 | 240 | 0.100 |
Why?
|
| Medical Records | 1 | 2013 | 447 | 0.100 |
Why?
|
| Surgical Procedures, Operative | 1 | 2015 | 358 | 0.100 |
Why?
|
| Cause of Death | 3 | 2009 | 787 | 0.100 |
Why?
|
| Walking | 1 | 2014 | 274 | 0.100 |
Why?
|
| Peptide Fragments | 2 | 2009 | 1327 | 0.100 |
Why?
|
| DNA, Bacterial | 4 | 1997 | 604 | 0.100 |
Why?
|
| Platelet Count | 3 | 2020 | 491 | 0.100 |
Why?
|
| Aneurysm, False | 1 | 2013 | 143 | 0.100 |
Why?
|
| Decompression, Surgical | 1 | 2012 | 147 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2016 | 1232 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2023 | 2679 | 0.090 |
Why?
|
| Spinal Diseases | 1 | 2012 | 131 | 0.090 |
Why?
|
| Opioid-Related Disorders | 1 | 2016 | 415 | 0.090 |
Why?
|
| Biopsy | 1 | 2019 | 3544 | 0.090 |
Why?
|
| Smoking Cessation | 2 | 2015 | 768 | 0.090 |
Why?
|
| Life Expectancy | 2 | 2009 | 129 | 0.090 |
Why?
|
| Hemoglobins | 2 | 2015 | 485 | 0.090 |
Why?
|
| Lymph Nodes | 1 | 2021 | 3080 | 0.090 |
Why?
|
| Spinal Fusion | 1 | 2012 | 150 | 0.090 |
Why?
|
| Weight Loss | 1 | 2015 | 639 | 0.090 |
Why?
|
| Cross Infection | 1 | 2015 | 548 | 0.090 |
Why?
|
| Vaccines, Synthetic | 2 | 2022 | 371 | 0.090 |
Why?
|
| Patient Readmission | 1 | 2015 | 592 | 0.090 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 2010 | 36 | 0.090 |
Why?
|
| Recurrence | 1 | 2019 | 4887 | 0.090 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2014 | 262 | 0.090 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2004 | 718 | 0.090 |
Why?
|
| Follow-Up Studies | 8 | 2021 | 15269 | 0.090 |
Why?
|
| Hypergammaglobulinemia | 1 | 2010 | 23 | 0.090 |
Why?
|
| Immunosuppressive Agents | 1 | 2016 | 1442 | 0.090 |
Why?
|
| Unsafe Sex | 1 | 2009 | 21 | 0.090 |
Why?
|
| Decision Support Techniques | 2 | 2012 | 605 | 0.090 |
Why?
|
| Sputum | 2 | 2023 | 158 | 0.080 |
Why?
|
| Liver Diseases | 2 | 2014 | 605 | 0.080 |
Why?
|
| Salvage Therapy | 1 | 2018 | 2119 | 0.080 |
Why?
|
| Predictive Value of Tests | 5 | 2020 | 4998 | 0.080 |
Why?
|
| Carrier Proteins | 1 | 2017 | 2139 | 0.080 |
Why?
|
| Lipids | 3 | 2014 | 662 | 0.080 |
Why?
|
| Quality of Life | 5 | 2012 | 4749 | 0.080 |
Why?
|
| Immunization Schedule | 2 | 2021 | 115 | 0.080 |
Why?
|
| Pandemics | 3 | 2023 | 1606 | 0.080 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 1 | 2008 | 27 | 0.080 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2009 | 105 | 0.080 |
Why?
|
| Hyperlipidemias | 2 | 2015 | 237 | 0.080 |
Why?
|
| Mental Health Services | 1 | 2011 | 256 | 0.080 |
Why?
|
| Adolescent | 9 | 2022 | 32687 | 0.080 |
Why?
|
| Immunotherapy | 1 | 2022 | 3546 | 0.080 |
Why?
|
| Telephone | 2 | 2020 | 160 | 0.080 |
Why?
|
| Patient Education as Topic | 1 | 2013 | 747 | 0.080 |
Why?
|
| Age Distribution | 3 | 2021 | 730 | 0.080 |
Why?
|
| Virginia | 2 | 2020 | 23 | 0.070 |
Why?
|
| Chronic Disease | 6 | 2014 | 1853 | 0.070 |
Why?
|
| Cats | 3 | 1997 | 174 | 0.070 |
Why?
|
| Benzodiazepines | 2 | 2019 | 174 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 2429 | 0.070 |
Why?
|
| Angiomatosis, Bacillary | 2 | 1997 | 9 | 0.070 |
Why?
|
| Hypertension | 2 | 2014 | 1624 | 0.070 |
Why?
|
| Feces | 2 | 2021 | 865 | 0.070 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2008 | 234 | 0.070 |
Why?
|
| Erectile Dysfunction | 1 | 2009 | 248 | 0.070 |
Why?
|
| Motor Activity | 1 | 2011 | 718 | 0.070 |
Why?
|
| Kidney Failure, Chronic | 1 | 2014 | 962 | 0.070 |
Why?
|
| Drug Therapy, Combination | 5 | 2012 | 2366 | 0.070 |
Why?
|
| Regression Analysis | 4 | 2013 | 1588 | 0.070 |
Why?
|
| Stroke | 1 | 2015 | 1094 | 0.070 |
Why?
|
| Sensitivity and Specificity | 4 | 2020 | 5195 | 0.070 |
Why?
|
| Critical Care | 1 | 2013 | 810 | 0.070 |
Why?
|
| Hypercholesterolemia | 1 | 2009 | 269 | 0.070 |
Why?
|
| Health Services | 1 | 2006 | 101 | 0.060 |
Why?
|
| Oligopeptides | 1 | 2008 | 451 | 0.060 |
Why?
|
| North America | 2 | 2016 | 341 | 0.060 |
Why?
|
| Socioeconomic Factors | 3 | 2020 | 1263 | 0.060 |
Why?
|
| Seasons | 2 | 2018 | 337 | 0.060 |
Why?
|
| Clofibric Acid | 1 | 2004 | 5 | 0.060 |
Why?
|
| Poisson Distribution | 2 | 2018 | 85 | 0.060 |
Why?
|
| Program Development | 1 | 2006 | 264 | 0.060 |
Why?
|
| Dyslipidemias | 1 | 2008 | 244 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2017 | 3947 | 0.060 |
Why?
|
| Evidence-Based Practice | 2 | 2019 | 130 | 0.060 |
Why?
|
| Prostatic Neoplasms | 1 | 2021 | 5996 | 0.060 |
Why?
|
| Specialization | 1 | 2005 | 129 | 0.060 |
Why?
|
| Mortality | 2 | 2019 | 354 | 0.060 |
Why?
|
| Interviews as Topic | 3 | 2016 | 520 | 0.060 |
Why?
|
| Actinomyces | 1 | 2003 | 5 | 0.060 |
Why?
|
| Statistics, Nonparametric | 4 | 2014 | 995 | 0.060 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2012 | 771 | 0.060 |
Why?
|
| Prognosis | 7 | 2020 | 22550 | 0.060 |
Why?
|
| B-Lymphocytes | 1 | 2010 | 1429 | 0.060 |
Why?
|
| Sex Factors | 3 | 2014 | 2206 | 0.060 |
Why?
|
| Medicine | 1 | 2005 | 140 | 0.060 |
Why?
|
| Myocardial Revascularization | 1 | 2024 | 135 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 6270 | 0.050 |
Why?
|
| Health Care Surveys | 2 | 2016 | 425 | 0.050 |
Why?
|
| Drug Resistance, Viral | 1 | 2003 | 70 | 0.050 |
Why?
|
| Lipodystrophy | 1 | 2002 | 39 | 0.050 |
Why?
|
| Immunoglobulin Variable Region | 2 | 2003 | 169 | 0.050 |
Why?
|
| Statistics as Topic | 1 | 2003 | 458 | 0.050 |
Why?
|
| Hemagglutination Inhibition Tests | 1 | 2022 | 121 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 2 | 2016 | 967 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2013 | 1534 | 0.050 |
Why?
|
| Patient Acuity | 1 | 2021 | 77 | 0.050 |
Why?
|
| Inappropriate Prescribing | 1 | 2022 | 52 | 0.050 |
Why?
|
| Self-Assessment | 1 | 2001 | 89 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2019 | 7791 | 0.050 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2022 | 135 | 0.050 |
Why?
|
| Kallikreins | 1 | 2021 | 86 | 0.050 |
Why?
|
| Liver Function Tests | 2 | 2011 | 186 | 0.050 |
Why?
|
| Feedback | 1 | 2022 | 227 | 0.050 |
Why?
|
| Pyridines | 1 | 2008 | 1312 | 0.050 |
Why?
|
| Minority Groups | 1 | 2023 | 321 | 0.050 |
Why?
|
| Blood Glucose | 2 | 2016 | 1286 | 0.040 |
Why?
|
| Vital Capacity | 1 | 2020 | 139 | 0.040 |
Why?
|
| Los Angeles | 1 | 2020 | 34 | 0.040 |
Why?
|
| Georgia | 1 | 2020 | 53 | 0.040 |
Why?
|
| Benzoxazines | 2 | 2012 | 26 | 0.040 |
Why?
|
| Alkynes | 2 | 2012 | 30 | 0.040 |
Why?
|
| New York | 1 | 2020 | 104 | 0.040 |
Why?
|
| Epidemiologic Methods | 2 | 2011 | 253 | 0.040 |
Why?
|
| Alcohol Abstinence | 1 | 2019 | 17 | 0.040 |
Why?
|
| Cyclopropanes | 2 | 2012 | 90 | 0.040 |
Why?
|
| Lung | 2 | 2018 | 3294 | 0.040 |
Why?
|
| Faculty, Medical | 1 | 2023 | 308 | 0.040 |
Why?
|
| Genotype | 2 | 2020 | 4266 | 0.040 |
Why?
|
| Bartonella henselae | 2 | 1997 | 22 | 0.040 |
Why?
|
| Reproducibility of Results | 3 | 2016 | 6210 | 0.040 |
Why?
|
| Bacterial Typing Techniques | 2 | 1997 | 142 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2021 | 1327 | 0.040 |
Why?
|
| Autoimmune Diseases | 1 | 2002 | 433 | 0.040 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 1998 | 101 | 0.040 |
Why?
|
| Peliosis Hepatis | 1 | 1997 | 2 | 0.040 |
Why?
|
| Absenteeism | 1 | 2018 | 22 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 493 | 0.040 |
Why?
|
| Disease Progression | 4 | 2012 | 6910 | 0.040 |
Why?
|
| Protective Factors | 1 | 2018 | 108 | 0.040 |
Why?
|
| Conjunctivitis | 1 | 1997 | 28 | 0.040 |
Why?
|
| Plasma | 1 | 2018 | 147 | 0.040 |
Why?
|
| Antibody Formation | 2 | 1997 | 386 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2021 | 320 | 0.040 |
Why?
|
| Geriatric Assessment | 1 | 2019 | 293 | 0.040 |
Why?
|
| Reference Values | 2 | 2014 | 1155 | 0.040 |
Why?
|
| Efficiency, Organizational | 1 | 2018 | 94 | 0.040 |
Why?
|
| Occupational Exposure | 1 | 2019 | 249 | 0.040 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 1998 | 242 | 0.040 |
Why?
|
| Immunization Programs | 1 | 2018 | 70 | 0.040 |
Why?
|
| Reagins | 1 | 2017 | 3 | 0.040 |
Why?
|
| Prostate-Specific Antigen | 1 | 2021 | 1039 | 0.040 |
Why?
|
| Endothelium, Vascular | 1 | 2002 | 898 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2022 | 1497 | 0.040 |
Why?
|
| Phylogeny | 1 | 2020 | 870 | 0.040 |
Why?
|
| Simian virus 40 | 1 | 1998 | 248 | 0.040 |
Why?
|
| Species Specificity | 2 | 1995 | 810 | 0.040 |
Why?
|
| CD4-CD8 Ratio | 1 | 2016 | 57 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2022 | 2619 | 0.040 |
Why?
|
| Physicians | 1 | 2005 | 870 | 0.040 |
Why?
|
| Polyomavirus Infections | 1 | 1998 | 149 | 0.030 |
Why?
|
| Carrier State | 1 | 1997 | 85 | 0.030 |
Why?
|
| Sulfonylurea Compounds | 1 | 2016 | 34 | 0.030 |
Why?
|
| Diagnostic Errors | 1 | 2021 | 531 | 0.030 |
Why?
|
| Injections, Intramuscular | 1 | 2017 | 249 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2021 | 1827 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 3651 | 0.030 |
Why?
|
| Tumor Virus Infections | 1 | 1998 | 249 | 0.030 |
Why?
|
| Drug Resistance, Microbial | 1 | 1997 | 243 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2016 | 2337 | 0.030 |
Why?
|
| Pharynx | 1 | 1997 | 150 | 0.030 |
Why?
|
| Disease Outbreaks | 2 | 2015 | 405 | 0.030 |
Why?
|
| South America | 1 | 2016 | 54 | 0.030 |
Why?
|
| Opiate Substitution Treatment | 1 | 2016 | 32 | 0.030 |
Why?
|
| Infant | 3 | 2021 | 13936 | 0.030 |
Why?
|
| Cell Movement | 2 | 2002 | 2504 | 0.030 |
Why?
|
| Opportunistic Infections | 2 | 2002 | 237 | 0.030 |
Why?
|
| Antigens, Viral | 1 | 1998 | 520 | 0.030 |
Why?
|
| Survivors | 1 | 2021 | 1025 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2016 | 124 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2013 | 4891 | 0.030 |
Why?
|
| Immunization, Secondary | 1 | 1996 | 116 | 0.030 |
Why?
|
| Coronary Disease | 2 | 2011 | 783 | 0.030 |
Why?
|
| Diabetes Mellitus | 2 | 2015 | 1076 | 0.030 |
Why?
|
| Blood Bactericidal Activity | 1 | 1995 | 27 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2017 | 223 | 0.030 |
Why?
|
| Respiratory Burst | 1 | 1995 | 22 | 0.030 |
Why?
|
| Thiazolidinediones | 1 | 2016 | 154 | 0.030 |
Why?
|
| Bartonella Infections | 1 | 1995 | 7 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 1996 | 269 | 0.030 |
Why?
|
| Leg | 1 | 2016 | 216 | 0.030 |
Why?
|
| Men's Health | 1 | 2015 | 21 | 0.030 |
Why?
|
| Consensus Sequence | 1 | 1995 | 120 | 0.030 |
Why?
|
| Health Policy | 1 | 2018 | 280 | 0.030 |
Why?
|
| Immunologic Surveillance | 1 | 1995 | 61 | 0.030 |
Why?
|
| Complement Activation | 1 | 1995 | 95 | 0.030 |
Why?
|
| Causality | 1 | 2015 | 177 | 0.030 |
Why?
|
| Canada | 1 | 2016 | 441 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 1995 | 464 | 0.030 |
Why?
|
| Hepatitis B virus | 1 | 2016 | 225 | 0.030 |
Why?
|
| Animals | 9 | 2016 | 62823 | 0.030 |
Why?
|
| Urban Health | 1 | 2014 | 84 | 0.030 |
Why?
|
| Asymptomatic Infections | 1 | 2014 | 35 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 1996 | 1061 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2014 | 4352 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2001 | 884 | 0.030 |
Why?
|
| Chromatography, Thin Layer | 1 | 2013 | 70 | 0.030 |
Why?
|
| Antigens, Bacterial | 1 | 1996 | 374 | 0.030 |
Why?
|
| 3T3-L1 Cells | 1 | 2013 | 75 | 0.030 |
Why?
|
| Air Pollutants | 1 | 1996 | 135 | 0.030 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2014 | 98 | 0.030 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1995 | 473 | 0.030 |
Why?
|
| Social Stigma | 1 | 2014 | 74 | 0.030 |
Why?
|
| Phenytoin | 1 | 1994 | 83 | 0.030 |
Why?
|
| Rabbits | 1 | 1995 | 1077 | 0.030 |
Why?
|
| Peritonitis | 1 | 2014 | 101 | 0.030 |
Why?
|
| PPAR alpha | 1 | 2013 | 63 | 0.030 |
Why?
|
| Fluconazole | 1 | 1994 | 109 | 0.030 |
Why?
|
| Albumins | 1 | 2015 | 267 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2015 | 485 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2015 | 422 | 0.030 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2014 | 94 | 0.030 |
Why?
|
| Cytomegalovirus | 1 | 1996 | 493 | 0.030 |
Why?
|
| Ascites | 1 | 2014 | 216 | 0.030 |
Why?
|
| Computer Simulation | 2 | 2009 | 1572 | 0.030 |
Why?
|
| Bronchoscopy | 1 | 1996 | 481 | 0.030 |
Why?
|
| Ceftriaxone | 1 | 2013 | 77 | 0.030 |
Why?
|
| Alcohols | 1 | 2012 | 24 | 0.030 |
Why?
|
| Urine | 1 | 2013 | 142 | 0.030 |
Why?
|
| HIV Antibodies | 1 | 2013 | 95 | 0.030 |
Why?
|
| Peripheral Arterial Disease | 1 | 2016 | 272 | 0.030 |
Why?
|
| User-Computer Interface | 1 | 2014 | 304 | 0.030 |
Why?
|
| Emtricitabine | 1 | 2012 | 7 | 0.030 |
Why?
|
| DNA Primers | 1 | 1995 | 1513 | 0.030 |
Why?
|
| PPAR gamma | 1 | 2013 | 231 | 0.030 |
Why?
|
| Registries | 1 | 2020 | 2252 | 0.030 |
Why?
|
| Tenofovir | 1 | 2012 | 22 | 0.030 |
Why?
|
| Blood | 1 | 2013 | 172 | 0.030 |
Why?
|
| Metformin | 1 | 2016 | 395 | 0.030 |
Why?
|
| Rickettsiaceae | 1 | 1992 | 1 | 0.030 |
Why?
|
| Rickettsiaceae Infections | 1 | 1992 | 3 | 0.030 |
Why?
|
| Radiography, Abdominal | 1 | 2013 | 124 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2022 | 6489 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2019 | 2287 | 0.030 |
Why?
|
| Perception | 1 | 2014 | 351 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 2013 | 235 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2013 | 909 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2018 | 2457 | 0.020 |
Why?
|
| Organophosphonates | 1 | 2012 | 63 | 0.020 |
Why?
|
| Patient Care | 1 | 2013 | 151 | 0.020 |
Why?
|
| Radiography, Thoracic | 1 | 2014 | 474 | 0.020 |
Why?
|
| Drug Administration Schedule | 2 | 2008 | 3540 | 0.020 |
Why?
|
| Linear Models | 1 | 2014 | 1100 | 0.020 |
Why?
|
| Overweight | 1 | 2015 | 489 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2012 | 354 | 0.020 |
Why?
|
| Nurse Administrators | 1 | 2011 | 5 | 0.020 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2014 | 349 | 0.020 |
Why?
|
| Pelvis | 1 | 2013 | 384 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2017 | 1295 | 0.020 |
Why?
|
| Child | 3 | 2021 | 30499 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2013 | 486 | 0.020 |
Why?
|
| Patient Participation | 1 | 2014 | 449 | 0.020 |
Why?
|
| Ambulatory Care Facilities | 1 | 2013 | 302 | 0.020 |
Why?
|
| Neutrophils | 1 | 1995 | 876 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 1992 | 738 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2013 | 612 | 0.020 |
Why?
|
| Vancomycin | 1 | 1992 | 292 | 0.020 |
Why?
|
| Risk | 1 | 2014 | 1950 | 0.020 |
Why?
|
| Bacterial Infections | 1 | 2014 | 507 | 0.020 |
Why?
|
| Radiography | 1 | 2014 | 1993 | 0.020 |
Why?
|
| Pharmacists | 1 | 2011 | 97 | 0.020 |
Why?
|
| Health Surveys | 1 | 2011 | 402 | 0.020 |
Why?
|
| Acute Disease | 1 | 2015 | 2514 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2016 | 919 | 0.020 |
Why?
|
| Poverty | 1 | 2013 | 478 | 0.020 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2009 | 68 | 0.020 |
Why?
|
| Pulmonary Fibrosis | 1 | 2010 | 175 | 0.020 |
Why?
|
| Syndrome | 2 | 2002 | 1405 | 0.020 |
Why?
|
| Adenine | 1 | 2012 | 669 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2015 | 1317 | 0.020 |
Why?
|
| Osteoporosis | 1 | 2011 | 236 | 0.020 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 2008 | 20 | 0.020 |
Why?
|
| Atazanavir Sulfate | 1 | 2008 | 7 | 0.020 |
Why?
|
| Proteins | 1 | 2017 | 2058 | 0.020 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2008 | 62 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2011 | 633 | 0.020 |
Why?
|
| Length of Stay | 1 | 2015 | 2015 | 0.020 |
Why?
|
| Medicare | 1 | 2013 | 934 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2014 | 1603 | 0.020 |
Why?
|
| Mice | 4 | 2016 | 36054 | 0.020 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2007 | 55 | 0.020 |
Why?
|
| Psychiatry | 1 | 2011 | 275 | 0.020 |
Why?
|
| Sexual Behavior | 1 | 2009 | 321 | 0.020 |
Why?
|
| Survival Rate | 1 | 2020 | 12533 | 0.020 |
Why?
|
| Professional Practice | 1 | 2007 | 81 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2013 | 1190 | 0.020 |
Why?
|
| Self Disclosure | 1 | 2006 | 30 | 0.020 |
Why?
|
| Adjuvants, Immunologic | 1 | 2010 | 692 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2012 | 1378 | 0.020 |
Why?
|
| Awareness | 1 | 2007 | 115 | 0.020 |
Why?
|
| Hematologic Tests | 1 | 2006 | 85 | 0.020 |
Why?
|
| Fatty Acids | 2 | 2002 | 448 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 2003 | 4993 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2021 | 13993 | 0.020 |
Why?
|
| Gene Expression Regulation | 2 | 2009 | 4200 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2013 | 4371 | 0.020 |
Why?
|
| Medical Audit | 1 | 2006 | 198 | 0.020 |
Why?
|
| Hypertension, Pulmonary | 1 | 2010 | 472 | 0.020 |
Why?
|
| Focus Groups | 1 | 2006 | 285 | 0.020 |
Why?
|
| Antigens, CD | 2 | 2004 | 1436 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2008 | 906 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 1996 | 7827 | 0.020 |
Why?
|
| Quality Control | 1 | 2006 | 467 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 3072 | 0.020 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2006 | 249 | 0.020 |
Why?
|
| B7-2 Antigen | 1 | 2004 | 53 | 0.020 |
Why?
|
| L-Selectin | 1 | 2004 | 36 | 0.010 |
Why?
|
| CD11b Antigen | 1 | 2004 | 65 | 0.010 |
Why?
|
| Myeloblastin | 1 | 2004 | 65 | 0.010 |
Why?
|
| Metabolic Syndrome | 1 | 2008 | 374 | 0.010 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2004 | 116 | 0.010 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2004 | 60 | 0.010 |
Why?
|
| Professional Competence | 1 | 2005 | 134 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2006 | 545 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2004 | 344 | 0.010 |
Why?
|
| Lymphocytes | 2 | 2002 | 1280 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2009 | 3646 | 0.010 |
Why?
|
| DNA, Ribosomal | 1 | 2003 | 105 | 0.010 |
Why?
|
| Anemia | 1 | 2009 | 730 | 0.010 |
Why?
|
| Immunoglobulin Idiotypes | 1 | 2003 | 53 | 0.010 |
Why?
|
| Serine Endopeptidases | 1 | 2004 | 280 | 0.010 |
Why?
|
| Genes, Immunoglobulin | 1 | 2003 | 87 | 0.010 |
Why?
|
| Esterification | 1 | 2002 | 16 | 0.010 |
Why?
|
| Risk-Taking | 1 | 2003 | 131 | 0.010 |
Why?
|
| Asthma | 1 | 2010 | 894 | 0.010 |
Why?
|
| Glycerol | 1 | 2002 | 107 | 0.010 |
Why?
|
| Income | 1 | 2003 | 232 | 0.010 |
Why?
|
| Lipolysis | 1 | 2002 | 108 | 0.010 |
Why?
|
| Triglycerides | 1 | 2004 | 622 | 0.010 |
Why?
|
| Demography | 1 | 2003 | 435 | 0.010 |
Why?
|
| Cholesterol | 1 | 2004 | 681 | 0.010 |
Why?
|
| Seroepidemiologic Studies | 1 | 2001 | 137 | 0.010 |
Why?
|
| Insurance, Health | 1 | 2003 | 263 | 0.010 |
Why?
|
| Education, Medical | 1 | 2005 | 344 | 0.010 |
Why?
|
| Organ Size | 1 | 2002 | 727 | 0.010 |
Why?
|
| Fasting | 1 | 2002 | 350 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2002 | 718 | 0.010 |
Why?
|
| Adipocytes | 1 | 2002 | 308 | 0.010 |
Why?
|
| Hepatocytes | 1 | 2002 | 351 | 0.010 |
Why?
|
| Hepacivirus | 1 | 2003 | 423 | 0.010 |
Why?
|
| Morbidity | 1 | 2001 | 405 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2004 | 1732 | 0.010 |
Why?
|
| Mercaptoethanol | 1 | 1998 | 16 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 2002 | 498 | 0.010 |
Why?
|
| Patient Selection | 1 | 2006 | 2043 | 0.010 |
Why?
|
| Binding Sites, Antibody | 1 | 1998 | 128 | 0.010 |
Why?
|
| Hepatitis B | 1 | 2001 | 274 | 0.010 |
Why?
|
| Phthiraptera | 1 | 1997 | 1 | 0.010 |
Why?
|
| Siphonaptera | 1 | 1997 | 8 | 0.010 |
Why?
|
| DNA | 1 | 2006 | 3089 | 0.010 |
Why?
|
| Adipose Tissue | 1 | 2002 | 735 | 0.010 |
Why?
|
| Disease Management | 1 | 2003 | 1111 | 0.010 |
Why?
|
| Jews | 1 | 1997 | 57 | 0.010 |
Why?
|
| Molecular Epidemiology | 1 | 1997 | 247 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 2002 | 1004 | 0.010 |
Why?
|
| Immunity | 1 | 1998 | 356 | 0.010 |
Why?
|
| Sulfur Dioxide | 1 | 1996 | 6 | 0.010 |
Why?
|
| Orthomyxoviridae | 1 | 1996 | 62 | 0.010 |
Why?
|
| Disease Reservoirs | 1 | 1995 | 40 | 0.010 |
Why?
|
| Cat-Scratch Disease | 1 | 1995 | 34 | 0.010 |
Why?
|
| Adenoviruses, Human | 1 | 1996 | 191 | 0.010 |
Why?
|
| Antigen-Antibody Complex | 1 | 1995 | 127 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 1997 | 484 | 0.010 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 1996 | 172 | 0.010 |
Why?
|
| Bacteriological Techniques | 1 | 1995 | 123 | 0.010 |
Why?
|
| Complement System Proteins | 1 | 1995 | 136 | 0.010 |
Why?
|
| Temperature | 1 | 1996 | 540 | 0.010 |
Why?
|
| Research Design | 1 | 2001 | 1581 | 0.010 |
Why?
|
| Immunization | 1 | 1996 | 402 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2004 | 3853 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1997 | 1650 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2003 | 5330 | 0.010 |
Why?
|
| Pedigree | 1 | 1997 | 2036 | 0.010 |
Why?
|
| Viral Proteins | 1 | 1995 | 493 | 0.010 |
Why?
|
| Drug Interactions | 1 | 1994 | 584 | 0.010 |
Why?
|
| RNA, Bacterial | 1 | 1992 | 84 | 0.010 |
Why?
|
| Glycoproteins | 1 | 1996 | 792 | 0.010 |
Why?
|
| HLA Antigens | 1 | 1995 | 588 | 0.010 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1992 | 245 | 0.010 |
Why?
|
| Liver | 1 | 2001 | 3124 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 1995 | 1011 | 0.010 |
Why?
|
| Brain | 1 | 2003 | 4252 | 0.010 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 1992 | 508 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1995 | 1136 | 0.010 |
Why?
|
| Seizures | 1 | 1994 | 1032 | 0.000 |
Why?
|
| Mutation | 1 | 2008 | 15941 | 0.000 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2003 | 7929 | 0.000 |
Why?
|
| Cytokines | 1 | 1995 | 2841 | 0.000 |
Why?
|
| Base Sequence | 1 | 1992 | 5500 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1992 | 6782 | 0.000 |
Why?
|
| Phenotype | 1 | 1995 | 6516 | 0.000 |
Why?
|
| Apoptosis | 1 | 1995 | 7837 | 0.000 |
Why?
|
| Child, Preschool | 1 | 1996 | 17006 | 0.000 |
Why?
|